Valuation: Aura Biosciences, Inc.

Market Cap 725M 625M 592M 536M 1.01B 69.3B 1.01B 7.03B 2.7B 35.26B 2.72B 2.66B 111B P/E 2026 *
-4.2x
P/E 2027 * -4.61x
Enterprise Value 725M 625M 592M 536M 1.01B 69.3B 1.01B 7.03B 2.7B 35.26B 2.72B 2.66B 111B EV / Sales 2026 *
-
EV / Sales 2027 * 147x
Free-Float
92.25%
Yield 2026 *
-
Yield 2027 * -
1 day+0.07%
1 week-7.47%
Current month-2.58%
1 month-8.56%
3 months+9.13%
6 months+17.76%
Current year+28.35%
1 week 6.91
Extreme 6.91
7.56
1 month 6.91
Extreme 6.91
8.37
Current year 4.73
Extreme 4.73
9.54
1 year 4.73
Extreme 4.73
9.54
3 years 4.34
Extreme 4.345
12.38
5 years 4.34
Extreme 4.345
26.16
10 years 4.34
Extreme 4.345
26.16
Manager TitleAgeSince
Chief Executive Officer 53 2026-04-29
Director of Finance/CFO 53 2026-09-01
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 41 2019-03-31
Chairman 61 2020-12-31
Director/Board Member 55 2021-04-30
Date Insider Type Main position Quantity % Market Cap. Importance
9/1/26 Free

Chief Financial Officer

70,000 0.0675%
9/1/26 Free

Chief Operating Officer

400,000 0.3857%
9/1/26 Free

Chief Technology Officer

175,000 0.1687%
Change 5-day change 1-year change 3-year change Capi.($)
+0.07%-7.47%+13.19%-30.67% 725M
+1.77%-3.78%-1.43%+10.24% 45.48B
+0.21%-2.98%+337.74%+520.30% 43.68B
+1.74%-2.24%+39.82%+20.85% 43.09B
+1.38%-3.28%+6.84%+73.19% 39.4B
-1.44%-5.26%+8.97%+39.76% 31.91B
+0.87%-2.60% - - 17.31B
+0.75%-0.64%+19.75%+108.58% 16.4B
+2.69%+1.40%+15.09%+31.71% 14.24B
+1.93%-3.55%+82.00%+36.66% 13.28B
Average +0.99%-3.62%+58.00%+90.07% 26.55B
Weighted average by Cap. +0.99%-3.51%+74.92%+124.65%

Financials

2026 *2027 *
Net sales - 4.92M 4.24M 4.02M 3.64M 6.83M 471M 6.87M 47.72M 18.35M 239M 18.5M 18.09M 756M
Net income -154M -133M -125M -114M -213M -14.69B -214M -1.49B -573M -7.48B -578M -565M -23.62B -167M -144M -136M -124M -232M -15.96B -233M -1.62B -622M -8.12B -627M -614M -25.66B
Net Debt - -
Logo Aura Biosciences, Inc.
Aura Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision therapies for solid tumors that aim to preserve organ function. The Company’s lead candidate, bel-sar (AU-011), is in late-stage development for primary choroidal melanoma and in early-stage development in other ocular oncology indications and bladder cancer. It is developing bel-sar as a potential first-line vision-sparing treatment option for early intervention in small choroidal melanoma and/or indeterminate lesions, avoiding the need for radiotherapy and reducing the risk for metastasis for these patients. Bel-sar is a virus-like drug conjugate (VDC) consisting of a human papillomavirus (HPV)-derived virus-like particle (VLP) and a phthalocyanine dye, a light-activated cytotoxic payload. The Company’s platform is designed to enable the targeting of a broad range of solid tumors using VLP, that can be conjugated with drugs or loaded with nucleic acids to create VDCs.
Employees
113
Date Price Change Volume
26-09-11 US$6.995 +0.07% 830,854
26-09-10 US$6.990 -2.92% 785,541
26-09-09 US$7.200 -2.17% 465,897
26-09-08 US$7.360 -2.65% 507,752
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
6.995USD
Average target price
16.60USD
Spread / Average Target
+137.31%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AURA Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!